Generic Drugmakers Face Uncertain Future

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

After a recent spate of judicial and regulatory decisions, generic drugmakers face higher legal, regulatory and insurance costs. But there’s more. Smaller players are expected to find it more difficult to compete and the combined circumstances suggest that consolidation is going to accelerate, according to a report from Moody’s Investor Service. One key development was a recent ruling by the US Supreme Court that drugmakers can face lawsuits over so-called pay-to-delay patent settlements (more here).

Hey, check out all the research scientist jobs. Post your resume today!

Back to news